Literature DB >> 29796724

The clinical importance of medulloblastoma extent of resection: a systematic review.

Eric M Thompson1,2,3, Alexa Bramall4, James E Herndon5, Michael D Taylor6,7, Vijay Ramaswamy8.   

Abstract

BACKGROUND: Although the majority of current medulloblastoma adjuvant therapy protocols treat patients with ≥ 1.5 cm2 residual tumor as high risk with increased craniospinal irradiation, the true prognostic significance of extent of resection (EOR) in medulloblastoma is unknown.
OBJECTIVES: We sought to synthesize the body of literature on EOR and survival to determine if a definitive association exists. DATA SOURCES/ELIGIBILITY CRITERIA: A PubMed search was conducted for the terms "medulloblastoma" combined with "extent of resection," "overall survival," "progression free survival," "gross total resection," "near total resection," "partial resection," or "subtotal resection." Studies that performed a statistical analysis of EOR and survival were included.
RESULTS: Sixteen articles including 1489 patients found a statistically significant association between EOR and survival, 20 articles including 2335 patients did not find a significant association between EOR and survival, and 14 articles including 2950 patients had mixed results. The three articles that accounted for molecular subgroup found varying associations between EOR and progression free survival, while no association was found between EOR and overall survival. LIMITATIONS: This review is limited by inconsistent definitions of EOR, the retrospective nature of the articles analyzed, and infrequent use of multivariate statistical analyses.
CONCLUSIONS: The prognostic importance of EOR for medulloblastoma is unclear and warrants re-evaluation, particularly in the context of molecular subgrouping.

Entities:  

Keywords:  Extent of resection; Medulloblastoma; Residual; Subgroup; Surgery; Survival

Mesh:

Year:  2018        PMID: 29796724     DOI: 10.1007/s11060-018-2906-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  70 in total

1.  Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy.

Authors:  T Tomita; M Yasue; H H Engelhard; D G McLone; F Gonzalez-Crussi; K D Bauer
Journal:  Cancer       Date:  1988-02-15       Impact factor: 6.860

2.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

3.  Influence of a child's sex on medulloblastoma outcome.

Authors:  M D Weil; K Lamborn; M S Edwards; W M Wara
Journal:  JAMA       Date:  1998-05-13       Impact factor: 56.272

4.  Outcome and prognostic factors of radiation therapy for medulloblastoma.

Authors:  Stefan Rieken; Angela Mohr; Daniel Habermehl; Thomas Welzel; Katja Lindel; Olaf Witt; Andreas E Kulozik; Wolfgang Wick; Jürgen Debus; Stephanie E Combs
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-23       Impact factor: 7.038

5.  Secondary manifestation of medulloblastoma: metastases and local recurrences in 66 patients.

Authors:  U Sure; H Bertalanffy; S Isenmann; S Brandner; W J Berghorn; W Seeger; A Aguzzi
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

6.  Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.

Authors:  Arnold C Paulino; Mark Lobo; Bin S Teh; M Fatih Okcu; Michael South; E Brian Butler; Jack Su; Murali Chintagumpala
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

7.  Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

Authors:  Jacques Grill; Christian Sainte-Rose; Anne Jouvet; Jean-Claude Gentet; Odile Lejars; Didier Frappaz; François Doz; Xavier Rialland; Fabienne Pichon; Anne-Isabelle Bertozzi; Pascal Chastagner; Dominique Couanet; Jean-Louis Habrand; Marie-Anne Raquin; Marie-Cécile Le Deley; Chantal Kalifa
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

8.  Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Authors:  Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

9.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

10.  Medulloblastoma in children under the age of three years: a retrospective Canadian review.

Authors:  Donna L Johnston; Daniel Keene; Ute Bartels; Anne-Sophie Carret; Bruce Crooks; David D Eisenstat; Chris Fryer; Lucie Lafay-Cousin; Valerie Larouche; Albert Moghrabi; Beverly Wilson; Shayna Zelcer; Mariana Silva; Josee Brossard; Eric Bouffet
Journal:  J Neurooncol       Date:  2009-01-31       Impact factor: 4.130

View more
  10 in total

1.  Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy.

Authors:  Sujith Baliga; Sara Gallotto; Benjamin Bajaj; Jacqueline Lewy; Elizabeth Weyman; Miranda P Lawell; Beow Y Yeap; David E Ebb; Mary Huang; Paul Caruso; Alisa Perry; Robin M Jones; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

2.  Molecular correlates of cerebellar mutism syndrome in medulloblastoma.

Authors:  Rashad Jabarkheel; Nisreen Amayiri; Derek Yecies; Yuhao Huang; Sebastian Toescu; Liana Nobre; Donald J Mabbott; Sniya V Sudhakar; Prateek Malik; Suzanne Laughlin; Maisa Swaidan; Maysa Al Hussaini; Awni Musharbash; Geeta Chacko; Leni G Mathew; Paul G Fisher; Darren Hargrave; Ute Bartels; Uri Tabori; Stefan M Pfister; Kristian Aquilina; Michael D Taylor; Gerald A Grant; Eric Bouffet; Kshitij Mankad; Kristen W Yeom; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

Review 3.  Current medulloblastoma subgroup specific clinical trials.

Authors:  Eric M Thompson; David Ashley; Daniel Landi
Journal:  Transl Pediatr       Date:  2020-04

4.  Preoperative prediction of postoperative cerebellar mutism syndrome. Validation of existing MRI models and proposal of the new Rotterdam pCMS prediction model.

Authors:  Dhaenens Bae; Van Veelen Mlc; C E Catsman-Berrevoets
Journal:  Childs Nerv Syst       Date:  2020-02-18       Impact factor: 1.475

5.  Risk Factors Associated with Post-therapeutic Outcome for Medulloblastoma: An Experience from Indonesia.

Authors:  David Tandian; Alphadenti Harlyjoy; Setyo Widi Nugroho; Syaiful Ichwan
Journal:  Asian J Neurosurg       Date:  2021-09-14

6.  Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification.

Authors:  Hee Won Cho; Hyunwoo Lee; Hee Young Ju; Keon Hee Yoo; Hong Hoe Koo; Do Hoon Lim; Ki Woong Sung; Hyung Jin Shin; Yeon-Lim Suh; Ji Won Lee
Journal:  J Korean Med Sci       Date:  2022-02-21       Impact factor: 2.153

Review 7.  The Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of Post-Radiotherapy Neurocognitive Decline and Outcomes.

Authors:  Nicholas Major; Neal A Patel; Josiah Bennett; Ena Novakovic; Dana Poloni; Mickey Abraham; Nolan J Brown; Julian L Gendreau; Ronald Sahyouni; Joshua Loya
Journal:  J Pers Med       Date:  2022-06-27

8.  Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis.

Authors:  Jingjing Ge; Baohong Wang; Shuai Zhao; Jiaju Xu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

9.  Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions.

Authors:  Musa Alharbi; Nahla Mobark; Yara Bashawri; Leen Abu Safieh; Albandary Alowayn; Rasha Aljelaify; Mariam AlSaeed; Amal Almutairi; Fatimah Alqubaishi; Ebtehal AlSolme; Maqsood Ahmad; Ayman Al-Banyan; Fahad E Alotabi; Jonathan Serrano; Matija Snuderl; May Al-Rashed; Malak Abedalthagafi
Journal:  Front Neurol       Date:  2020-03-20       Impact factor: 4.003

10.  Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas.

Authors:  Yan-Xia Wang; Haibo Wu; Yong Ren; Shengqing Lv; Chengdong Ji; Dongfang Xiang; Mengsi Zhang; Huimin Lu; Wenjuan Fu; Qing Liu; Zexuan Yan; Qinghua Ma; Jingya Miao; Ruili Cai; Xi Lan; Bin Wu; Wenying Wang; Yinhua Liu; Dai-Zhong Wang; Mianfu Cao; Zhicheng He; Yu Shi; Yifang Ping; Xiaohong Yao; Xia Zhang; Peng Zhang; Ji Ming Wang; Yan Wang; Youhong Cui; Xiu-Wu Bian
Journal:  Signal Transduct Target Ther       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.